Wednesday, March 05, 2025 | 03:24 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Shilpa Medicare gains 7% on EIR for Jadcherla formulations unit

The stock was 7% to Rs 488 on the BSE after the company received EIR from the USFDA for its formulation manufacturing facility in Telangana following the audit in November last year.

Pharmaceuticals, drugs, pharma industry, medical, health, lab
Premium

SI Reporter Mumbai
Shilpa Medicare has gained 7% to Rs 488 on the BSE in early morning trade after the company said that it has received Establishment Inspection Report (EIR) from the US drug regulator for its formulation manufacturing facility in Telangana following the audit in November last year.

“The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Shilpa Medicare Ltd's formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between 11th November and 30th November 2017,” Shipla Medicare on Saturday, March 16, 2018, said in a regulatory filing.

FDA has

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in